Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Peter Ellis, MD, MPH and Lydia S. Dugdale, MD, MAR
Presenting all, including expensive, options to all patients means advocating not only for individual patients, but also for a just health care system.
AMA J Ethics. 2019;21(1):E26-31. doi:
10.1001/amajethics.2019.26.
Patrick S. Phelan, Mary C. Politi, PhD, and Christopher J. Dy, MD, MPH
During immediate and long-term recovery periods, decisions must account for patients’ personal goals and possible clinical outcomes and should clarify what recovery means.
AMA J Ethics. 2020;22(5):E380-387. doi:
10.1001/amajethics.2020.380.